Extension Granted to DxS and BTG for ARMS Technology Licence Parameters
News Jan 13, 2006
ARMS is a method for the detection of gene mutations and single nucleotide polymorphisms.
Under an extension to their licence agreement with AstraZeneca, BTG and DxS are now able to grant licences under the technology rights to ARMS and related technologies from a combination of the licensable rights under both AstraZeneca and City of Hope patents (patent numbers US 5,595,890, US 5,137,806, US 5,639,611 and corresponding patents worldwide).
In March 2004, an agreement was signed with AstraZeneca giving DxS and BTG certain rights to the intellectual property with the aim of further commercialising the technology within the diagnostic and research markets.
The extension will allow DxS and BTG to maximise the commercial value for the ARMS™ technology.
This is being achieved via companies that offer products and services that relate to the detection of genetic variation, companies that are currently using ARMS™ technology as part of their in-house research activities, as well as encouraging applications for this technology.
Amplification Refractory Mutation System technology, as licensed from DxS and BTG, is a well-established and reliable method for the detection of genetic variations and single nucleotide polymorphisms.
Scientists believe SNP maps will help them identify the multiple genes associated with such complex diseases as cancer, diabetes, and vascular disease.
In addition, SNPs can help determine the likelihood that someone will develop a particular disease.
Furthermore, SNPs are useful in predetermining an individual's response to drug treatment, and can be used as markers to differentiate individuals with varying response to treatment.